Transcranial Magnetic Stimulation for Chemotherapy-Induced Neuropathy
This study is looking at how repetitive transcranial magnetic stimulation (rTMS) might help reduce pain for women who have chemotherapy-induced peripheral neuropathy (nerve damage causing pain, numbness, or tingling). You may be able to join if you are a woman aged 18 or older with breast or gynecologic cancer, and developed nerve pain from platinum-based drugs, taxanes, or vinca alkaloids, with a pain score of 4 or more. The study will measure success by looking at changes in your pain scores between the start and end of treatment. The current status of this study is unclear, and it plans to enroll 19 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 19 women.
- What's involved
- You would receive repetitive transcranial magnetic stimulation (rTMS) treatments Monday through Friday for two weeks, totaling 10 sessions.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your pain will be measured at 5 months after the start of the study to see how the treatment affected you.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07120100
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
Recruiting
NAAges 18+InterventionalTreatmentUniversity of UtahInvestigator-initiated
~19 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:rTMS
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Pain Numeric Rating Scale (PNRS) between screening and end of treatment in subjects who complete at least 7 rTMS treatments.
Measured over 5 months
Conditions
Where it's being run
1 sites across 1 statesUtah1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Female subjects aged ≥ 18 years.
Histologically confirmed breast or gynecologic cancer.
Developed neuropathic pain with the initiation of or within one month after completion of treatment with anti-neoplastic agents from the following class:
Platinum-based drugs
Taxanes
Vinca alkaloids
Pain score 4 or more on the Pain Numeric Rating Scale (PNRS).
Score 3 or more on the Douleur Neuropathique 4 (DN-4) questionnaire.
Subjects must have failed at least one standard-of-care neuropathic medication.
Subjects who are currently on neuropathic medication must have been on a stable dose for at least 6 weeks prior to enrollment.
For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:
Women \< 50 years of age:
Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or
Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
Women ≥ 50 years of age:
Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or
Had radiation-induced menopause with last menses \>1 year ago; or
Had chemotherapy-induced menopause with last menses \>1 year ago; or
Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
Subjects of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
Exclusion
Evidence of recurrent breast or gynecologic cancer at the time of enrollment.
Current or planned treatment with chemotherapy.
Note: Other anti-cancer treatments (e.g. hormone therapy and targeted therapies) are allowed at the Investigator's discretion.
History of seizure, epilepsy, or other conditions that would, in the opinion of the investigator, negatively impact the patient's safety or ability to participate in the study.
Presence of neuropathic pain unrelated to systemic cancer therapy, including but not limited to: painful diabetic neuropathy, HIV-induced neuropathy, neuropathic pain from radiation therapy and underlying cancer/other medical conditions.
Presence of implantable devices including spinal cord stimulators, dorsal root ganglion stimulators, deep brain stimulators, cochlear implants, intrathecal pain pumps, and intracranial metallic objects which are incompatible with rTMS administration in the opinion of the treating investigator.
Subjects on medications that, in the opinion of the investigator, significantly lower seizure threshold will be excluded.
Any condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
History of recent suicide attempt or active suicidal ideation that, in the opinion of the investigator, presents an increased risk for study participation
Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.
Enrollment in another study that, in the opinion of the investigator, would negatively impact study participation or cause undue burden for the subject.
What this trial measures
- Change in Pain Numeric Rating Scale (PNRS) between screening and end of treatment in subjects who complete at least 7 rTMS treatments.5 months
To assess the change in pain scores (0- no pain to 10-worst pain imaginable) after treatment with repetitive transcranial magnetic stimulation (rTMS) in patients with CIPN.